Economic Impacts of New Drugs

新药的经济影响

• 批准号: 6827197
• 负责人: RICHARD Gabriel FRANK
• 金额: $ 44.24万
• 依托单位: HARVARD MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-10 至 2007-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6827197
• 关键词: antipsychotic agents; clinical research; drug design /synthesis /production; health care cost /financing; health care policy; health care quality; health care service evaluation; health care service utilization; health insurance; health services research tag; human data; mental health services; meta analysis; psychopharmacology; psychotropic drugs; racial /ethnic difference; socioeconomics

DESCRIPTION (provided by applicant): Prescription drugs are central components to mental health treatments. Dramatic innovations in psychotropic drugs have occurred over the last 15 years. At the same time spending on psychotropic medications has increased at rates of over 15% per annum in recent years. These increases have been driven primarily by increases in the volume of psychotropic drugs used and by the prices of new drugs. Spending on new psychotropic medications has become a focus of both public and private policy makers. Some analysts have argued that one must look at the system wide effect of new drugs in order to judge their net impact on spending. This application proposes a program of research that will assess the net impact of new psychotropic drugs on health and mental health care spending by examining whether new psychotropic drugs "pay for themselves" by offsetting other health and mental health care costs. We will focus on three specific conditions: major depression, bipolar disorder and schizophrenia. Evidence will be assessed from clinical trials via the use of meta-analysis. The major thrust of the research will use data from a large insured population for the years 1991-2000 and from the Florida Medicaid program for the years 1993-2002. An econometric model will be specified and estimated using instrumental variables methods to bolster the inferences from the observational data. Finally, we will examine the proposition that offsets occur differentially across racial and ethnic groups, for high utilizers and according to the organization of insurance arrangements.

描述（由申请人提供）：处方药是心理健康治疗的核心组成部分。在过去的15年里，精神药物出现了戏剧性的创新。与此同时，近年来，精神药物的支出以每年15%以上的速度增长。这些增长主要是由于精神药物使用量的增加和新药物的价格。新的精神药物的支出已成为公共和私人决策者的重点。一些分析师认为，必须考虑新药的系统效应，以判断其对支出的净影响。本申请提出了一项研究计划，该计划将通过检查新的精神药物是否通过抵消其他健康和精神卫生保健费用来“为自己买单”，从而评估新的精神药物对健康和精神卫生保健支出的净影响。我们将集中在三个具体的条件：严重抑郁症，双相情感障碍和精神分裂症。将通过使用荟萃分析对临床试验的证据进行评估。这项研究的主要目的是利用1991-2000年大量投保人口的数据和1993-2002年佛罗里达医疗补助计划的数据。将使用工具变量方法指定和估计一个计量经济学模型，以支持从观察数据中得出的推论。最后，我们将研究的主张，抵消发生差异的种族和民族群体，高利用率，并根据组织的保险安排。